ArticleImmunology2009
Dexamethasone/1alpha-25-dihydroxyvitamin D3-treated dendritic cells suppress colitis in the SCID T-cell transfer model.
Article in Immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Article
- The emerging role of regulatory cell-based therapy in autoimmune disease.Frontiers in immunology · 2022Review
- Co-Stimulation-Impaired Bone Marrow-Derived Dendritic Cells Prevent Dextran Sodium Sulfate-Induced Colitis in Mice.Frontiers in immunology · 2018Article
- Make immunological peace not war: Potential applications of tolerogenic dendritic cells.Biomedical journal · 2017Article
- Harnessing the properties of dendritic cells in the pursuit of immunological tolerance.Biomedical journal · 2017Review
- Update on Dendritic Cell-Induced Immunological and Clinical Tolerance.Frontiers in immunology · 2017Review
- Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe Disease.Journal of pharmaceutical sciences · 2016Article
- Adoptive Transfer of Dendritic Cells Expressing Fas Ligand Modulates Intestinal Inflammation in a Model of Inflammatory Bowel Disease.Journal of clinical & cellular immunology · 2016Article
- Antibody Targeting of "Steady-State" Dendritic Cells Induces Tolerance Mediated by Regulatory T Cells.Frontiers in immunology · 2016Review
- Metabolism Is Central to Tolerogenic Dendritic Cell Function.Mediators of inflammation · 2016Review
- Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?World journal of stem cells · 2015Review
- Activation of the aryl hydrocarbon receptor affects activation and function of human monocyte-derived dendritic cells.Clinical and experimental immunology · 2014Article
- Regulatory dendritic cells for immunotherapy in immunologic diseases.Frontiers in immunology · 2014Review
- Tolerogenic Donor-Derived Dendritic Cells Risk Sensitization In Vivo owing to Processing and Presentation by Recipient APCs.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Dendritic cell-based approaches for therapeutic immune regulation in solid-organ transplantation.Journal of transplantation · 2013Review
- Therapeutic potential of tolerogenic dendritic cells in IBD: from animal models to clinical application.Clinical & developmental immunology · 2013Review
- Regulatory multitasking of tolerogenic dendritic cells - lessons taken from vitamin d3-treated tolerogenic dendritic cells.Frontiers in immunology · 2013Article
- Heligmosomoides polygyrus bakeri induces tolerogenic dendritic cells that block colitis and prevent antigen-specific gut T cell responses.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Gram-negative enterobacteria induce tolerogenic maturation in dexamethasone conditioned dendritic cells.PloS one · 2012Article
- Vitamin D3: a helpful immuno-modulator.Immunology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoantigen-presenting immunomodulatory dendritic cells (DCs) that are used for adoptive transfer have been shown to be a promising therapy for a number of autoimmune diseases. We have previously demonstrated that enteroantigen-pulsed DCs treated with interleukin-10 (IL-10) can partly protect severe combined immunodeficient (SCID) mice adoptively transferred with CD4+ CD25(-) T cells from the development of wasting disease and colitis. We therefore established an in vitro test that could predict the in vivo function of DCs and improve strategies for the preparation of immunomodulatory DCs in this model. Based on these in vitro findings, we here evaluate three methods for DC generation including short-term and long-term IL-10 exposure or DC exposure to dexamethasone in combination with vitamin D3 (Dex/D3). All DCs resulted in lower CD4+ CD25(-) T-cell enteroantigen-specific responses in vitro, but Dex/D3 DCs had the most prominent effect on T-cell cytokine secretion. In vivo, Dex/D3 DCs most efficiently prevented weight loss and gut pathology upon CD4+ CD25(-) T-cell transfer in SCID mice, although the effect on gut pathology was antigen independent. Our data in the SCID T-cell transfer model illustrate some correlation between in vitro and in vivo DC function and document that prevention of experimental inflammatory bowel disease by transfer of immunosuppressive DCs is possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.